FDA Adverse Event Injury Summary report: N

TAXUS EXPRESS2 PACLITAXEL-ELUTING CORONARY STENT SYSTEM

MDR report key: 1469163 · Received September 10, 2009

Report

Report Number
2134265-2009-04631
Event Type
Injury
Date Received
September 10, 2009
Date of Event
February 1, 2006
Report Date
August 11, 2009
Manufacturer
BOSTON SCIENTIFIC
Product Code
NIQ
PMA / PMN Number
P030025
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

IT IS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION; THEREFORE, A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. THE BATCH NUMBER IS UNK AND THE MANUFACTURING RECORDS FOR THE COMPLAINT DEVICE COULD NOT BE REVIEWED. THE ROOT CAUSE IS ANTICIPATED PROCEDURAL COMPLICATIONS AS THIS EVENT IS A KNOWN PHYSIOLOGICAL EFFECT OF THE PROCEDURE AND IS NOTED WITHIN THE DFU. LITERATURE CITATION: YA-LING H, XIAO-ZENG W, QUAN-MIN J, SHOU-LI W ET AL. COMPARISON OF RAPAMYCIN AND PACLITAXEL ELUTING STENT IN PTS WITH MULTI-VESSEL CORONARY DISEASE. CHINESE JOURNAL OF CARDIOLOGY 2006; 123-130.

Description of Event or Problem · 1

IT WAS REPORTED IN THE JOURNAL ARTICLE TITLED: COMPARISON OF RAPAMYCIN AND PACLITAXEL ELUTING STENT IN PTS WITH MULTI-VESSEL CORONARY DISEASE, THAT POST CORONARY DRUG ELUTING STENTING TREATMENT PROCEDURE, IN-STENT RESTENOSIS OCCURRED. DURING THE INITIAL PROCEDURE, AN UNSPECIFIED TAXUS EXPRESS2 PACLITAXEL-ELUTING CORONARY STENT WAS IMPLANTED. THE TARGET LESION LOCATION AND CHARACTERISTICS WERE NOT PROVIDED. AT SOME POINT POST-PROCEDURE, THE PT UNDERWENT SECONDARY VESSEL RECONSTRUCTION/ REVASCULARIZATION OF THE TARGET LESION DUE TO IN-STENT RESTENOSIS. NO FURTHER INFO IS AVAILABLE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TAXUS EXPRESS2 PACLITAXEL-ELUTING CORONARY STENT SYSTEM NIQ STENT, CORONARY, DRUG-ELUTING NIQ BOSTON SCIENTIFIC

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention